Welcome

Sign out Have a question? We're here to help

Copyright © 2019 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Galapagos NV (GLPG)

$121.18 3.57 (2.86%)

16:34 EDT GLPG Stock Quote Delayed 15 Minutes

Volume:

Previous Close $121.18

Market Cap 6.22B

PE Ratio -

EPS -

Volume (Avg. Vol.) 72,700

Day's Range 120.85 - 123.15

52-Week Range 85.00 - 125.48

Dividend & Yield N/A (N/A)

GLPG Stock Predictions, Articles, and Galapagos NV News

From InvestorPlace
From the Web

5 Clinical-Stage Biotech Stocks to Buy

By Aaron Levitt, InvestorPlace Contributor Feb 25, 2019

There are plenty of potential in clinical-stage biotech stocks. Here are five with some wonderful catalysts.

5 Beaten-Down Biotech Stocks to Pick Up from the Wreckage

By Aaron Levitt, InvestorPlace Contributor Oct 17, 2018

After the market's rout, biotech stocks offer a huge value right now. Here are 5 that offer the best opportunities for investors.

Biggest Movers in Manufacturing Stocks Now – BSPM RTTR SCL CCXI

By Portfolio Grader Oct 18, 2016

The following stocks were the biggest movers and shakers in the Manufacturing sector today.

Gilead Sciences, Inc. Is More Than an HCV Play (GILD)

By James Brumley, InvestorPlace Feature Writer Oct 12, 2016

Gilead Sciences (GILD) stock is a bargain at these prices. Traders just have yet to see the glass as half full.

The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana

From Benzinga Jun 12, 2019

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 11) BIOFRONTERA AG/ADR (...

H.C. Wainwright Believes Galapagos NV (GLPG) Still Has Room to Grow

From Smarter Analyst Jun 12, 2019

H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Galapagos NV (GLPG) today and set a price target of $150. The company's shares

H.C. Wainwright Believes Galapagos NV (NASDAQ: GLPG) Still Has Room to Grow

From Analyst Ratings Jun 12, 2019

H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Galapagos NV (GLPG – Research Report) today and set a price target of $150. The company’s shares closed yesterday at $122.75, close to its 52-week high of $125.48. Chattopadhyay commented: “Valuation and risks to our investment thesis. Our 12-month, $150 price target on shares of

Servier and Galapagos completes enrollment in knee OA study

From Seeking Alpha Jun 11, 2019

Servier and Galapagos NV (NASDAQ:GLPG) have completed recruitment for their ROCCELLA Phase 2 trial with GLPG1972/S201086, for patients with knee osteoarthritis (OA), ahead of schedule. The tr

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

From Benzinga Jun 8, 2019

Biotech stocks staged a steady recovery last week. ASCO presentations dominated the headlines, with Iovance Biotherapeutics Inc (NASDAQ: IOVA) and Mirati Therapeutics Inc (NASDAQ...

Best & Worst Performing Mid Cap Stocks for June 7, 2019

From StockNews.com Jun 7, 2019

<p><strong><a href="/stock/BHVN/">BHVN</a></strong> – BHVN leads the way today as the best performing mid cap stock, closing up 20.31%.</p>

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy

Free Report

10 Stocks Set for Monster Growth

He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!

Download your FREE COPY!